


Antidepressant agent 6

Cat. No.:	HY-157792
Molecular Formula:	C ₁₇ H ₂₀ FNO ₄
Molecular Weight:	321.34
Target:	mAChR
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antidepressant agent 6 (S-3a) is a lead compound with potent and sustained antidepressant effects. Antidepressant agent 6 (S-3a) displays high cognitive safety margin. Antidepressant agent 6 (S-3a) antagonizes M1 receptors and elevates BDNF levels, suggesting its potential as an antidepressant for further exploration ^[1] .								
In Vivo	<p>Antidepressant agent 6 (S-3a) alleviates depressive symptoms in mice and displays a higher cognitive safety margin than scopolamine^[1].</p> <p>Antidepressant agent 6 (S-3a) alleviates despair behavior in CRS mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Reserpine-Induced Depression Model in Mice^[1].</td> </tr> <tr> <td>Dosage:</td> <td>25, 100, or 300 µg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Administered intraperitoneally every other day.</td> </tr> <tr> <td>Result:</td> <td>Did not cause changes in total distance during the OFT, suggesting its antidepressant-like effects were independent of locomotor activity. Could alleviate depression-induced weight loss relative to the untreated model group.</td> </tr> </table>	Animal Model:	Reserpine-Induced Depression Model in Mice ^[1] .	Dosage:	25, 100, or 300 µg/kg.	Administration:	Administered intraperitoneally every other day.	Result:	Did not cause changes in total distance during the OFT, suggesting its antidepressant-like effects were independent of locomotor activity. Could alleviate depression-induced weight loss relative to the untreated model group.
Animal Model:	Reserpine-Induced Depression Model in Mice ^[1] .								
Dosage:	25, 100, or 300 µg/kg.								
Administration:	Administered intraperitoneally every other day.								
Result:	Did not cause changes in total distance during the OFT, suggesting its antidepressant-like effects were independent of locomotor activity. Could alleviate depression-induced weight loss relative to the untreated model group.								

REFERENCES

[1]. Le Wang, et al. Design, Synthesis, and Activity Evaluation of Fluorine-Containing Scopolamine Analogues as Potential Antidepressants. J Med Chem. 2024 Feb 14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA